Cinacalcet HCl controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis.

Coyne, DW; Jadoul, Michel; Stegman, MH; Azad, H; Joy, MS; Mischel, SF; Pokroy, N; Ouseph, R; Gokal, R; Brink, HS; Olson, KA; Albizem, MB; Klassen, PS; Chertow, GM

Cinacalcet HCl controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis.

Coyne, DW

;

Jadoul, Michel

;

Stegman, MH

;

Azad, H

;

Chertow, GM

;et.al.

(2003) 36th Annual Meeting of the American-Society-of-Nephrology — Location: SAN DIEGO (California) (12.November.2003)

Files

No attached file found for this publication.

Details

Authors

Coyne, DW
Author
Jadoul, MichelUCLouvain
Author
Stegman, MH
Author
Azad, H
Author
Chertow, GM
Author

Affiliations

Citations

APA
Chicago
FWB

Coyne, D., Jadoul, M., Stegman, M., Azad, H., Joy, M., Mischel, S., Pokroy, N., Ouseph, R., Gokal, R., Brink, H., Olson, K., Albizem, M., Klassen, P., & Chertow, G. (2003). Cinacalcet HCl controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis. Journal of the American Society of Nephrology, 14, 464A-464A. https://hdl.handle.net/2078.5/141244 (Original work published 2003)